加载中
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
前收盘价
US$218.42
−US$4.03 · -1.81%
盘前
US$220.05
+US$1.6303 · +0.75%
10月12日 4:09 ET
盘中时间采用ET。市场数据可能有所延迟。
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
日内区间
当前US$218.42
52周区间
当前US$218.42
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
54
合理估值
情绪
57
多空交织
风险
17
低风险
动量
66
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
日内区间
当前US$218.42
52周区间
当前US$218.42
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 42.68亿 USD | 40.69亿 USD | 38.34亿 USD | 36.59亿 USD | 30.94亿 USD |
| 销货成本 | 5.03亿 USD | 4.46亿 USD | 4.36亿 USD | 5.41亿 USD | 4.41亿 USD |
| 毛利 | 37.64亿 USD | 36.23亿 USD | 33.99亿 USD | 31.19亿 USD | 26.53亿 USD |
| 研究与开发 | 7.83亿 USD | 8.84亿 USD | 8.5亿 USD | 5.9亿 USD | 5.06亿 USD |
| 销售、一般及管理费用 | 18.09亿 USD | 13.85亿 USD | 13.43亿 USD | 14.17亿 USD | 14.52亿 USD |
| 营业费用 | 35.4亿 USD | 29.07亿 USD | 28.2亿 USD | 31.84亿 USD | 24.83亿 USD |
| 利息支出 | 1.95亿 USD | 2.38亿 USD | 2.89亿 USD | 2.88亿 USD | 2.79亿 USD |
| 折旧和摊销 | 6.96亿 USD | 6.6亿 USD | 6.39亿 USD | 6.29亿 USD | 5.52亿 USD |
| 营业利润 | 2.24亿 USD | 7.17亿 USD | 5.79亿 USD | −6552.8万 USD | 1.7亿 USD |
| 净利润 | −3.56亿 USD | 5.6亿 USD | 4.15亿 USD | −2.24亿 USD | −3.29亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$292.8
上涨空间 34.05%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4.74亿0.02%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB3.44亿0.18%1853亿 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR2.18亿0.32%682亿 USD0.05%US$234.43+0.22%
Vanguard Extended Market ETFVXF1.83亿0.19%954亿 USD0.05%US$235+0.80%
Invesco S&P MidCap Momentum ETFXMMO1.54亿2.15%71.38亿 USD0.34%US$148.79+0.96%
VictoryShares Free Cash Flow ETFVFLO1.45亿1.27%114.45亿 USD0.44%US$52.84-0.11%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.08亿0.42%258.17亿 USD0.23%US$669.87+0.54%
Dimensional - US Targeted Value ETFDFAT7845.21万0.26%301.22亿 USD0.33%US$67.27-0.43%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOVictoryShares Free Cash Flow ETFVFLOState Street SPDR S&P MIDCAP 400 ETF TrustMDYDimensional - US Targeted Value ETFDFATAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
